A clinical trial is a controlled study to evaluate the safety and efficacy (how well it works) of an experimental drug treatment. These studies are required before a drug can be approved by a regulatory agency such as the Food and Drug Administration (FDA) or European Medicines Agency (EMA). The purpose of a clinical trial is to evaluate whether a potential new therapy is safe and effective. Patients interested in participating in a clinical trial must meet certain eligibility criteria and be willing to follow directions of the physician in charge of the study.

 

Vaccinex is currently conducting three clinical trials:

  • The SIGNAL study, which is a potentially pivotal trial evaluating the safety and efficacy of our drug pepinemab in patients with Huntington’s disease (click here for more details)
  • The SIGNAL-AD study, which is a Phase 1b/2a trial evaluating the safety and efficacy of our drug pepinemab in patients with Alzheimer’s disease (click here for more details)
  • CLASSICAL-Lung, which is a Phase 1b/2 trial evaluating the safety and efficacy of a combination of pepinemab and Merck KGaA’s checkpoint inhibitor, avelumab, in patients with non-small cell lung cancer (click here for more details)

 

We are not currently recruiting new patients to join our trials.

 

Company Policy on Expanded Access and Compassionate Use